The discovery of the CD4/CD8–p56lck complexes and the identification of the targets of the initiated phosphorylation cascade have given rise to the development of chimeric antigen receptor (CAR) T-cell immunotherapy in combating cancer and infections [84,85] (Figure 3). The gene discussed is LCK; the disease is cancer.